Activated PI3K Delta Syndrome (APDS) Therapeutic Market (Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 – 2028)

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Activated PI3K Delta Syndrome (APDS) Therapeutic Market (Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 – 2028)

  • 215 Pages | Published On: 1-Jun-17 | Format:PDF | Last Updated: Updation in process
  • GervanoRA’s Market Estimation report “Activated PI3K Delta Syndrome (APDS): Opportunity Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018–2028)” analyzed the current and upcoming opportunities in the Activated PI3K Delta Syndrome (APDS) area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Activated PI3K Delta Syndrome (APDS) industry. The report has been divided into segments like Disease Overview, Market Overview and Pipeline Analysis to provide in depth insights about the market dynamics and ongoing R&D in the Activated PI3K Delta Syndrome (APDS) area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography,Pipeline Molecules by ROA , Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Activated PI3K Delta Syndrome (APDS) Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed drugs to provide a brief understanding about the market opportunities in the Activated PI3K Delta Syndrome (APDS) competitive environment. We have also prognosticated the Activated PI3K Delta Syndrome (APDS) market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Estimated Pipeline Drug Approval Timelines
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis

  • TABLE OF CONTENTS
    1 INTRODUCTION
    1.1 RELATED UPCOMING REPORTS
    1.2 ABOUT GERVANORA
    2 EXECUTIVE SUMMARY
    2.1 EXECUTIVE PERSPECTIVE
    2.2 KEY INFLECTION POINTS IN APDS MARKET (2010-2028)
    2.3 PRODUCT LIFE CYCLE MANAGEMENT (LCM) STRATEGIES
    2.4 KEY MAJOR FINDINGS
    2.4.1 DRIVERS
    2.4.2 RESTRAINTS
    2.4.3 UNMET NEEDS AND OPPORTUNITY
    3 MARKET OVERVIEW
    3.1 GOVERNMENT REGULATORY DYNAMICS AND IMPACT
    3.2 PRICING AND REIMBURSEMENT
    3.3 DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    3.4 PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    3.5 PIPELINE ANALYSIS
    3.5.1 PIPELINE ANALYSIS BY GEOGRAPHY
    3.5.2 PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    3.5.3 PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    3.5.4 ESTIMATED LAUNCH TIMELINE FOR PIPELINE PRODUCTS
    3.5.5 POTENTIAL FUTURE PIPELINE BASED ON MOA
    4 DISEASE OVERVIEW
    4.1 DISEASE DEFINITION & SYMPTOMS
    4.2 DISEASE CAUSE AND CLASSIFICATION
    4.3 DISEASE DIAGNOSIS
    4.4 TREATMENT ALGORITHM & GUIDELINES
    5 GLOBAL APDS THERAPEUTIC MARKET BY DRUG CLASS
    5.1 TARGETED THERAPIES
    5.1.1 SMALL MOLECULES
    5.1.1.1 UNMET NEEDS AND OPPORTUNITIES
    5.1.1.2 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY
    5.2 NON-TARGETED THERAPIES
    5.2.1 ANTI-INFECTIVE MOLECULES
    5.2.1.1 MARKET TRENDS AND GROWTH FACTORS
    5.2.1.2 UNMET NEEDS AND OPPORTUNITIES
    5.2.1.3 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY
    5.2.2 IMMUNOMODULATORS
    5.2.2.1 MARKET TRENDS AND GROWTH FACTORS
    5.2.2.2 UNMET NEEDS AND OPPORTUNITIES
    5.2.2.3 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY
    6 GLOBAL APDS THERAPEUTIC MARKET BY ROUTE OF ADMINISTRATION
    6.1 ORALS
    6.1.1 MARKET TRENDS AND GROWTH FACTORS
    6.1.2 UNMET NEEDS AND OPPORTUNITIES
    6.1.3 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY
    6.2 INHALATIONAL
    6.2.1 MARKET TRENDS AND GROWTH FACTORS
    6.2.2 UNMET NEEDS AND OPPORTUNITIES
    6.2.3 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY
    6.3 INJECTABLES
    6.3.1 MARKET TRENDS AND GROWTH FACTORS
    6.3.2 UNMET NEEDS AND OPPORTUNITIES
    6.3.3 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY
    7 GLOBAL APDS THERAPEUTIC MARKET BY AGE GROUP
    7.1 ADULTS
    7.1.1 MARKET TRENDS AND GROWTH FACTORS
    7.1.2 UNMET NEEDS AND OPPORTUNITIES
    7.1.3 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY
    7.2 PEDIATRICS
    7.2.1 MARKET TRENDS AND GROWTH FACTORS
    7.2.2 UNMET NEEDS AND OPPORTUNITIES
    7.2.3 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY
    8 GLOBAL APDS THERAPEUTIC MARKET BY GEOGRAPHY
    8.1 UNITED STATES
    8.1.1 CURRENT MARKET TRENDS
    8.1.2 EMERGING OPPORTUNITIES
    8.1.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.2 UNITED KINGDOM
    8.2.1 CURRENT MARKET TRENDS
    8.2.2 EMERGING OPPORTUNITIES
    8.2.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.3 GERMANY
    8.3.1 CURRENT MARKET TRENDS
    8.3.2 EMERGING OPPORTUNITIES
    8.3.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.4 FRANCE
    8.4.1 CURRENT MARKET TRENDS
    8.4.2 EMERGING OPPORTUNITIES
    8.4.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.5 ITALY
    8.5.1 CURRENT MARKET TRENDS
    8.5.2 EMERGING OPPORTUNITIES
    8.5.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.6 SPAIN
    8.6.1 CURRENT MARKET TRENDS
    8.6.2 EMERGING OPPORTUNITIES
    8.6.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.7 JAPAN
    8.7.1 CURRENT MARKET TRENDS
    8.7.2 EMERGING OPPORTUNITIES
    8.7.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.8 CHINA
    8.8.1 CURRENT MARKET TRENDS
    8.8.2 EMERGING OPPORTUNITIES
    8.8.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.9 INDIA
    8.9.1 CURRENT MARKET TRENDS
    8.9.2 EMERGING OPPORTUNITIES
    8.9.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.1 BRAZIL
    8.10.1 CURRENT MARKET TRENDS
    8.10.2 EMERGING OPPORTUNITIES
    8.10.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.11 RUSSIA
    8.11.1 CURRENT MARKET TRENDS
    8.11.2 EMERGING OPPORTUNITIES
    8.11.3 MARKET SIZE (2017), FORECAST (2018-2028)
    8.12 ROW
    8.12.1 CURRENT MARKET TRENDS
    8.12.2 EMERGING OPPORTUNITIES
    8.12.3 MARKET SIZE (2017), FORECAST (2018-2028)
    9 COMPANY PROFILES
    9.1 GLAXOSMITHKLINE
    9.1.1 COMPANY SNAPSHOT
    9.1.2 BUSINESS PERFORMANCE
    9.1.3 KEY OPERATING SEGMENTS
    9.1.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.1.5 SWOT ANALYSIS
    9.2 NOVARTIS
    9.2.1 COMPANY SNAPSHOT
    9.2.2 BUSINESS PERFORMANCE
    9.2.3 KEY OPERATING SEGMENTS
    9.2.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.2.5 SWOT ANALYSIS
    9.3 RHIZEN PHARMACEUTICALS
    9.3.1 COMPANY SNAPSHOT
    9.3.2 BUSINESS PERFORMANCE
    9.3.3 KEY OPERATING SEGMENTS
    9.3.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.3.5 SWOT ANALYSIS
    9.4 ASTRAZENECA
    9.4.1 COMPANY SNAPSHOT
    9.4.2 BUSINESS PERFORMANCE
    9.4.3 KEY OPERATING SEGMENTS
    9.4.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.4.5 SWOT ANALYSIS
    9.5 INCYTE
    9.5.1 COMPANY SNAPSHOT
    9.5.2 BUSINESS PERFORMANCE
    9.5.3 KEY OPERATING SEGMENTS
    9.5.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.5.5 SWOT ANALYSIS
    9.6 TG THERAPEUTICS
    9.6.1 COMPANY SNAPSHOT
    9.6.2 BUSINESS PERFORMANCE
    9.6.3 KEY OPERATING SEGMENTS
    9.6.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.6.5 SWOT ANALYSIS
    9.7 BAYER
    9.7.1 COMPANY SNAPSHOT
    9.7.2 BUSINESS PERFORMANCE
    9.7.3 KEY OPERATING SEGMENTS
    9.7.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.7.5 SWOT ANALYSIS
    9.8 GILEAD
    9.8.1 COMPANY SNAPSHOT
    9.8.2 BUSINESS PERFORMANCE
    9.8.3 KEY OPERATING SEGMENTS
    9.8.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.8.5 SWOT ANALYSIS
    9.9 ROCHE (GENENTECH)
    9.9.1 COMPANY SNAPSHOT
    9.9.2 BUSINESS PERFORMANCE
    9.9.3 KEY OPERATING SEGMENTS
    9.9.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.9.5 SWOT ANALYSIS
    9.1 VERASTEM
    9.10.1 COMPANY SNAPSHOT
    9.10.2 BUSINESS PERFORMANCE
    9.10.3 KEY OPERATING SEGMENTS
    9.10.4 MAJOR PRODUCTS AND PIPELINE ANALYSIS
    9.10.5 SWOT ANALYSIS
    10 APPENDIX
    10.1.1 KEY POINT OF CONTACTS / LEAD INVESTIGATORS

    LIST OF TABLES

    TABLE 1 HIGH-PRICED ORPHAN DRUGS
    TABLE 2 DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    TABLE 3 PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    TABLE 4 APDS PIPELINE ANALYSIS
    TABLE 5 ESTIMATED LAUNCH OF PIPELINE PRODUCTS
    TABLE 6 FUTURE PIPELINE MOLECULES FOR APDS
    TABLE 7 IMMUNE LEVEL EVALUATION OF PATIENT
    TABLE 8 MARKET SIZE (2017), FORECAST (2018-2028) BY DRUG CLASS ($1000)
    TABLE 9 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY ($MILLION)
    TABLE 10 LENIOLISIB’S DOSAGE
    TABLE 11 CLINICAL TRIALS OF NOVARTIS’ CDZ173
    TABLE 12 CLINICAL TRIALS OF GSK’S GSK-2269557
    TABLE 13 CLINICAL TRIALS OF UCB PHARMA’ SELATALISIB (UCB 5857)
    TABLE 14 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY ($MILLION)
    TABLE 15 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY ($MILLION)
    TABLE 16 APDS PATIENTS (N=53) SUMMARY OF IMMUNOGLOBULIN CHARACTERISTICS
    TABLE 17 MARKET SIZE (2017), FORECAST (2018-2028) BY COUNTRY ($MILLION)
    TABLE 18 MARKET SIZE (2017), FORECAST (2018-2028) BY ROA
    TABLE 19 MARKET SIZE (2017), FORECAST (2018-2028) BY AGE GROUP
    TABLE 20 MARKET SIZE (2017), FORECAST (2018-2028) – UNITED STATES
    TABLE 21 MARKET SIZE (2017), FORECAST (2018-2028) – UNITED KINGDOM
    TABLE 22 MARKET SIZE (2017), FORECAST (2018-2028) – GERMANY
    TABLE 23 MARKET SIZE (2017), FORECAST (2018-2028) – FRANCE
    TABLE 24 MARKET SIZE (2017), FORECAST (2018-2028) – ITALY
    TABLE 25 MARKET SIZE (2017), FORECAST (2018-2028) – SPAIN
    TABLE 26 MARKET SIZE (2017), FORECAST (2018-2028) – JAPAN
    TABLE 27 MARKET SIZE (2017), FORECAST (2018-2028) – CHINA
    TABLE 28 MARKET SIZE (2017), FORECAST (2018-2028) – INDIA
    TABLE 29 MARKET SIZE (2017), FORECAST (2018-2028) – BRAZIL
    TABLE 30 MOST PREVALENT RARE DISEASES FOUND IN RUSSIA
    TABLE 31 MARKET SIZE (2017), FORECAST (2018-2028) – RUSSIA
    TABLE 32 MARKET SIZE (2017), FORECAST (2018-2028) – ROW
    TABLE 33 COMPANY OVERVIEW; GSK
    TABLE 34 MAJOR PRODUCTS: GSK
    TABLE 35 PIPELINE PRODUCTS: GSK
    TABLE 36 COMPANY SNAPSHOT: NOVARTIS
    TABLE 37 MAJOR PRODUCTS: NOVARTIS
    TABLE 38 LATE STAGE ONCOLOGY PIPELINE: NOVARTIS
    TABLE 39 CARDIOVASCULAR AND METABOLISM PIPELINE: NOVARTIS
    TABLE 40 RESPIRATORY PIPELINE PRODUCTS: NOVARTIS
    TABLE 41 IMMUNOLOGY AND DERMATOLOGY PIPELINE PRODUCTS: NOVARTIS
    TABLE 42 NEUROSCIENCE PIPELINE: NOVARTIS
    TABLE 43 INFECTIOUS DISEASE PIPELINE: NOVARTIS
    TABLE 44 OPHTHALMOLOGY PIPELINE: NOVARTIS
    TABLE 45 COMPANY SNAPSHOT: RHIZEN
    TABLE 46 PIPELINE ANALYSIS: RHIZEN
    TABLE 47 COMPANY SNAPSHOT: ASTRAZENECA
    TABLE 48 MAJOR PRODUCTS: ASTRAZENECA
    TABLE 49 ONCOLOGY PIPELINE: ASTRAZENECA
    TABLE 50 CARDIOVASCULAR AND METABOLIC DISEASE PIPELINE: ASTRAZENECA
    TABLE 51 RESPIRATORY PIPELINE: ASTRAZENECA
    TABLE 52 COMPANY SNAPSHOT: INCYTE
    TABLE 53 MAJOR PRODUCTS: INCYTE
    TABLE 54 PIPELINE ANALYSIS: INCYTE
    TABLE 55 PARTNERED PROGRAMS: INCYTE
    TABLE 56 LOSS OF PATENTS: INCYTE
    TABLE 57 COMPANY OVERVIEW: TG THERAPEUTICS
    TABLE 58 PIPELINE ANALYSIS: TG THERAPEUTICS
    TABLE 59 COMPANY SNAPSHOT: BAYER
    TABLE 60 MAJOR PRODUCTS: BAYER
    TABLE 61 LATE-STAGE PIPELINE DRUGS: BAYER
    TABLE 62 COMPANY SNAPSHOT: GILEAD
    TABLE 63 MAJOR PRODUCTS: GILEAD
    TABLE 64 PIPELINE ANALYSIS: GILEAD
    TABLE 65 PATENT EXPIRY OF MARKETED PRODUCTS
    TABLE 66 COMPANY SNAPSHOT: ROCHE
    TABLE 67 MAJOR PRODUCTS: ROCHE
    TABLE 68 LATE-STAGE PIPELINE PRODUCTS: ROCHE
    TABLE 69 PHASE IINE PIPELINE PRODUCTS: ROCHE
    TABLE 70 COMPANY SNAPSHOT: VERASTEM
    TABLE 71 PIPELINE ANALYSIS: VERASTEM
    TABLE 72 RAPID INCREASE IN R&D EXPENSES: VERASTEM

    LIST OF FIGURES

    FIGURE 1 KEY INFLECTION POINTS IN APDS MARKET, 2010 – 2030
    FIGURE 2 TOTAL PERCENT OF PHARMACEUTICAL SPENDING, 2015
    FIGURE 3 PATENTS GRANTED IN THE US AND OUTSIDE US
    FIGURE 4 PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 5 PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    FIGURE 6 EFFECTIVE TARGETED THERAPY FOR APDS
    FIGURE 7 LOCATION OF P110-DELTA MUTATIONS IN APDS
    FIGURE 8 PI3KCD PATIENT CLINICAL DEMOGRAPHICS
    FIGURE 9 CONCENTRATION RESPONSE CURVES OF SELETALISIB IN THE PI3K? COMPETITIVE TR-FRET ASSAY
    FIGURE 10 APDS PIPELINE BY ROUTE OF ADMINISTRATION
    FIGURE 11 APDS MARKET BY GEOGRAPHY
    FIGURE 12 TOTAL HEALTH SPENDING, USD/CAPITA – UNITED STATES
    FIGURE 13 TOTAL HEALTH SPENDING, USD/CAPITA – UNITED KINGDOM
    FIGURE 14 TOTAL HEALTH SPENDING, USD/CAPITA – GERMANY
    FIGURE 15 TOTAL HEALTH SPENDING, USD/CAPITA – FRANCE
    FIGURE 16 TOTAL HEALTH SPENDING, USD/CAPITA – ITALY
    FIGURE 17 TOTAL HEALTH SPENDING, USD/CAPITA – SPAIN
    FIGURE 18 TOTAL HEALTH SPENDING, USD/CAPITA – JAPAN
    FIGURE 19 BUSINESS PERFORMANCE: GSK
    FIGURE 20 BUSINESS PERFORMANCE: NOVARTIS
    FIGURE 21 RHIZEN’S BUSINESS STRATEGY
    FIGURE 22 BUSINESS PERFORMANCE: ASTRAZENECA
    FIGURE 23 ANNUAL REVENUE: INCYTE STRENGTH
    FIGURE 24 ANNUAL REVENUE MIX 2017: INCYTE
    FIGURE 25 PRODUCTIVE LATER-STAGE DEVELOPMENT CANDIDATES
    FIGURE 26 ANNUAL R&D INVESTMENTS IN $
    FIGURE 27 BUSINESS PERFORMANCE: GILEAD
    FIGURE 28 DIFFERENT PRODUCTS IN VARIOUS THERAPAUTIC AREAS: GILEAD
    FIGURE 29 REDUCTION IN ANNUAL REVENUES AND R&D EXPENSES: GILEAD
    FIGURE 30 AREAS OF FOCUS ON PHARMA’S MAJOR MARKETS: GILEAD
    FIGURE 31 BUSINESS PERFORMANCE: ROCHE

Pricing

Individual Pricing $3500

Corporate Pricing $3500

Enterprise Pricing $3500

(We are offering all the above license types for a single price!!)